Oragenics and Intrexon announce encouraging results in lantibiotic testing

|By:, SA News Editor

Oragenics (OGEN +1.3%) and recent IPO Intrexon (XON -2%) say that collaborative experiments demonstrate a genetically-modified host can be engineered to produce improved titers of OGEN's lead compound MU1140, progressing towards the commercial production of lantibiotics, a novel-class of broad-spectrum antibiotics.

The collaboration also uncovered two new methods of purifying its lead compound resulting in higher purity and yields of MU1140.

OGEN and XON entered into an Exclusive Channel Collaboration agreement to develop and commercialize lantibiotics for the treatment of infectious diseases in June 2012.